Navigation Links
Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
Date:3/16/2009

rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the return of development and commercialization rights to blinatumomab, the future development of blinatumomab and a new BiTE antibody binding to CD19,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... Jan. 29 CuraGen Corporation (Nasdaq: CRGN ), ... and calendar year of 2008 and provided milestone and ... three month period ended December 31, 2008, CuraGen utilized ... fourth quarter with $88 million of cash and investments. ...
... development and production, today announced the appointment of David Pyrce as its ... ... Los Angeles (PRWEB) January 29, 2009 -- Nexsun Corp, a leader in ... David Pyrce as its Chief Executive Officer and member of the Board ...
... (Nasdaq: SGMO ) today announced that the ... financial results on Wednesday, February 4, 2009, after the ... a conference call at 5:00 p.m. ET, which will ... During the conference call, the company will review the ...
Cached Biology Technology:CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 2CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 3CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 4CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 5CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 6Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 3
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... University of Adelaide has opened the way for the development ... , In Australia, annual barley production is second only to ... one of the most important diseases of barley. , Senior ... composition of special growths on the cell walls of barley ... leaf. , The research, by the ARC Centre of Excellence ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2New hope for powdery mildew resistant barley 2
... contamination of drinking water does not have a ... of Wisconsin-Madison researchers on arsenic-tainted wells shows that ... the contamination. Naturally occurring arsenic in rocks ... where it poses no threat to groundwater, explains ...
... maps that allow conservationists to estimate the distribution of ... threatened species and those with specific habitats, according to ... Conservation Biology. Our study found that species ranges ... trend is particularly pronounced for birds that are threatened, ...
... dinosaur from the Early Jurassic has been discovered in ... Glacialisaurus hammeri and lived about 190 million years ago. ... is based on partial foot, leg and ankle bones ... Antarctica at an elevation of more than 13,000 feet. ...
Cached Biology News:Arsenic contamination lacks one-size-fits-all remedy 2Arsenic contamination lacks one-size-fits-all remedy 3Threatened birds may be rarer than geographic range maps suggest 2Threatened birds may be rarer than geographic range maps suggest 3Massive dinosaur discovered in Antarctica sheds light on life, distribution of sauropodomorphs 2
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
FRACTALKINE [Human] (Recombinant)...
... head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps and bath ... * ... ... ...
... The Luminex® 200 System with ... for developing single and multi-analyte assays ... contains the new, powerful user friendly ... user can design specific templates for ...
Biology Products: